Bremner D A, Dickie A S, Singh K P
Department of Clinical Microbiology, Auckland Hospital, New Zealand.
J Antimicrob Chemother. 1988 Oct;22 Suppl D:19-23. doi: 10.1093/jac/22.supplement_d.19.
The in-vitro activity of fleroxacin (Ro23-6240), a new synthetic quinolone, was compared with that of three other quinolones against 665 clinical isolates of aerobic bacteria by the agar dilution technique. Fleroxacin showed similar activity to norfloxacin, enoxacin and pefloxacin against most isolates of Enterobacteriaceae, Neisseria meningitidis, N. gonorrhoeae, Haemophilis influenzae, Staphylococcus spp. and streptococcus faecalis. Fleroxacin was the most active quinolone against Enterobacter spp. Fleroxacin was not as active against Pseudomonas aeruginosa, but the MIC90 (4 mg/l) is still below the reported peak serum level after a standard oral dose of 400 mg.
采用琼脂稀释技术，将新型合成喹诺酮类药物氟罗沙星（Ro23 - 6240）与其他三种喹诺酮类药物对665株需氧菌临床分离株的体外活性进行了比较。氟罗沙星对大多数肠杆菌科细菌、脑膜炎奈瑟菌、淋病奈瑟菌、流感嗜血杆菌、葡萄球菌属和粪肠球菌分离株的活性与诺氟沙星、依诺沙星和培氟沙星相似。氟罗沙星对肠杆菌属细菌的活性最强。氟罗沙星对铜绿假单胞菌的活性不如其他药物，但在400mg标准口服剂量后，其MIC90（4mg/l）仍低于报道的血清峰值水平。
